EUVIMEDEUVIMED entdecken
Klinische Studie

Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease‐modifying therapy

Parul Rai iD, Subodh Selukar iD, Yu Bi iD, Shuyan Chen, Anthony Merlocco iD, Cara E Morin iD, Chris Goode, Jeffrey A Towbin iD, Mark Rushing iD, Michael A Rebolledo iD, Vijaya Joshi, Alexis Leonard iD und 7 weitere

British Journal of Haematology · 2026-11 · 209 (5) · 2244-2251

DOI: 10.1111/bjh.70891 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 18.10.2026. Verfasst von Parul Rai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Anemia, Sickle Cell, Cardiomyopathies. Die Arbeit nennt 20 Literaturangaben. Gefördert von: NHLBI NIH HHS, American Lebanese Syrian Associated Charities, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic haematopoietic stem cell transplantation (HSCT) is curative for sickle cell disease (SCD) ‐ a group of inherited haemoglobin disorders encompassing homozygous haemoglobin S (HbSS) and compound heterozygous sickling disorders, including haemoglobin SC disease (HbSC), haemoglobin S/β 0 ‐thalassaemia (HbSβ 0 ), haemoglobin S/β + ‐thalassaemia (HbSβ + ), etc., but its long‐term impact on SCD myocardial remodelling is incompletely characterized. We performed serial cardiac magnetic resonance imaging (CMR) and echocardiography in children and young adults with SCD undergoing matched‐sibling or haploidentical HSCT in a prospective clinical trial with up to 36 months of post‐HSCT follow‐up. CMR assessments were conducted before HSCT and through the post‐HSCT period. Echocardiographic parameters at 12 months post HSCT were compared with those of age‐matched participants receiving disease‐modifying therapies (DMTs). Among 20 HSCT recipients (mean age 14.8 years), CMR demonstrated progressive reductions in biventricular volumes and left atrial volume over 36 months, with preservation of ejection fraction. Extra‐cellular volume, a surrogate marker of myocardial fibrosis, showed significant improvement from baseline, having normalized in nearly all participants assessed at 36 months. Compared with age‐matched DMT recipients, HSCT recipients had lower tricuspid regurgitant jet velocity and improved diastolic parameters at 12 months post‐HSCT, with normalization of cardiac output on echocardiography. These findings demonstrate sustained reversal of myocardial fibrosis and structural cardiac remodelling after HSCT for SCD. HSCT may, therefore, modify the trajectory of SCD cardiomyopathy beyond the improvements achieved with current DMTs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationAnemia, Sickle CellCardiomyopathiesHumansAdolescentFemaleMaleChildYoung AdultAdultEchocardiographyProspective StudiesMagnetic Resonance ImagingTreatment Outcome

Stichwörter der Autor:innen

cardiac outcomesdisease‐modifying therapieshaematopoietic stem cell transplantsickle cell disease

Autor:innen und Institutionen

  • Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Division of Pediatric Cardiology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Division of Pediatric Radiology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Department of Radiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatric Radiology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.

ORCID-Profile: Parul Rai, Subodh Selukar, Yu Bi, Anthony Merlocco, Cara E Morin, Jeffrey A Towbin, Mark Rushing, Michael A Rebolledo, Alexis Leonard, Jane S Hankins, Clifford M Takemoto, Stephen Gottschalk, Brandon Triplett, Jason N Johnson, Akshay Sharma

Förderung

  • NHLBI NIH HHS
  • American Lebanese Syrian Associated Charities
  • NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health

Zitieren

APA

Rai, P., Selukar, S., Bi, Y., Chen, S., Merlocco, A., Morin, C. E., Goode, C., Towbin, J. A., Rushing, M., Rebolledo, M. A., Joshi, V., Leonard, A., Hankins, J. S., Manwani, D., Takemoto, C. M., Gottschalk, S., Triplett, B., Johnson, J. N., & Sharma, A. (2026). Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease‐modifying therapy. British Journal of Haematology, 209(5), 2244-2251. https://doi.org/10.1111/bjh.70891

Vancouver

Rai P, Selukar S, Bi Y, Chen S, Merlocco A, Morin CE, et al. Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease‐modifying therapy. British Journal of Haematology. 2026;209(5):2244-2251. doi:10.1111/bjh.70891

BibTeX
@article{Rai2026,
  author = {Rai, Parul and Selukar, Subodh and Bi, Yu and Chen, Shuyan and Merlocco, Anthony and Morin, Cara E and Goode, Chris and Towbin, Jeffrey A and Rushing, Mark and Rebolledo, Michael A and Joshi, Vijaya and Leonard, Alexis and Hankins, Jane S and Manwani, Deepa and Takemoto, Clifford M and Gottschalk, Stephen and Triplett, Brandon and Johnson, Jason N and Sharma, Akshay},
  title = {Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease‐modifying therapy},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2244--2251},
  doi = {10.1111/bjh.70891}
}
Kostenlos starten →